

Europäisches Patentamt  
European Patent Office  
Office européen des brevets



(11) EP 1 205 201 A1

(12)

## EUROPEAN PATENT APPLICATION

(43) Date of publication:  
15.05.2002 Bulletin 2002/20

(51) Int Cl.7: A61M 15/00

(21) Application number: 01309421.4

(22) Date of filing: 07.11.2001

(84) Designated Contracting States:  
AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU  
MC NL PT SE TR  
Designated Extension States:  
AL LT LV MK RO SI

(30) Priority: 13.11.2000 EP 00310050

(71) Applicant: THE TECHNOLOGY PARTNERSHIP  
PUBLIC LIMITED COMPANY  
Melbourn Royston Hertfordshire SG8 6EE (GB)

(72) Inventors:  
• Blakey, David Mark  
Herts CM23 4EE (GB)  
• Pollock, Neil  
Herts SG8 7DW (GB)  
• Sant, Andrew Jonathan  
Cambridge CB1 3SX (GB)

(74) Representative: Brunner, Michael John  
GILL JENNINGS & EVERY,  
Broadgate House,  
7 Eldon Street  
London EC2M 7LH (GB)

(54) **Aerosol drug dispensing device with dispensing chamber having walls surface coated with or formed of fluoropolymer**

(57) An aerosol drug dispensing device (25) provides a metered dose of a pharmacologically active liquid (7) to a holding reservoir (18) from which the dose

is then dispensed as an aerosol spray. The holding reservoir (18) has a containment wall or walls (22) having a surface coated with or formed of a fluoropolymer.




Figure 1

EP 1 205 201 A1

## Description

[0001] This invention relates to aerosol drug dispensing devices and, in particular, to those devices in which the drug to be dispensed is retained within a reservoir prior to being dispensed.

[0002] It is well known that, prior to dispensing a pharmacologically active liquid as an aerosol spray, the liquid may be retained within a holding reservoir in the drug dispensing device. The liquid is usually provided as a metered dose from a bulk supply within the device such that the device can be used for multiple dosing.

[0003] One disadvantage of traditional holding reservoirs is that significant amounts of the pharmacologically active liquid may be retained within the holding reservoir after liquid is supposed to have been dispensed. When this is the case, the user of the drug dispensing device does not obtain the correct dosage and therefore the treatment may not be fully effective. Alternatively, extra liquid must be provided within the reservoir to compensate for the portion which is retained within the holding reservoir. This leads to increased costs as more liquid than should be required is supplied.

[0004] Our earlier International patent application, WO95/15822, discloses a dispensing apparatus having a perforate membrane through which droplets are dispensed. The perforate membrane is provided with a number of perforations having a reverse taper, namely a larger cross-sectional area at that face of the membrane away from which liquid droplets emerge than at the opposite face of the membrane, from which opposite face liquid flows in use to replace that in the emerging droplet spray.

[0005] WO 99/42154 discloses a drug delivery device for dispensing a metered dose of medicament. The device is provided with at least one internal surface which comes into contact with the medicament during storage or dispensing that has at least one layer of cold plasma polymerised monomers bonded thereto, the monomer being selected from the group of materials comprising perfluoro-cyclohexane, perfluoro-hexane, tetrafluoroethylene, trifluoroethylene, vinylidene fluoride, vinyl fluoride, fluoroethylene and fluoropropylene.

[0006] The present invention aims to provide an aerosol drug dispensing device which overcomes the above problems.

[0007] According to the present invention, there is provided an aerosol drug dispensing device in which a metered dose of a pharmacologically active liquid is provided to a holding reservoir from which the dose is then dispensed as an aerosol spray through a perforate membrane having perforations having a reverse taper, namely a larger cross-sectional area at that face of the membrane away from which liquid droplets emerge than at the opposite face of the membrane, characterised in that:

the holding reservoir has a containment wall or

walls having a surface coated with or formed of a fluoropolymer.

[0008] It has been found that the use of a fluoropolymer walled holding reservoir reduces the residual volume of drug suspension or solution left in the reservoir after spraying. This is due to the non-wetting characteristics of the fluoropolymer wall and to its low drug retention properties, that is suspended drug particles remain in suspension as they do not readily adhere to the fluoropolymer wall.

[0009] Preferably, the holding reservoir is coated with or formed from polytetrafluoroethylene (PTFE).

[0010] The holding reservoir may be provided with an inlet for receiving the pharmacologically active liquid from a supply means. Preferably, the perforate membrane is formed from a metal.

[0011] An embodiment of the present invention will now be described with reference to the accompanying drawings, in which:

Fig. 1 shows a cross sectional side view of a device according to the present invention;

Figs. 2 to 6 show successive stages during operation of the device of Fig. 1;

Fig. 7 shows a trigger circuit for controlling the dispensing of the pharmacologically active liquid; and Figs. 8a and 8b illustrate, in section, preferred forms of the perforate membrane for the device of Fig. 1.

[0012] As can be seen from Figs. 1 to 6, a drug dispensing device 25 forming part of a drug delivery system has a hollow casing 1 in which a reservoir body 2 is slidably mounted. A spray head mounting assembly 3 is attached to one end of the casing 1, the mounting assembly 3 comprising spray head assembly 3a, clamping means 4, diaphragm clamp 11a and seal 17. A main return spring 5 is provided between a recess 29 in the casing 1 and the reservoir body 2 to support the reservoir body 2, biased towards its topmost position (as shown), within the casing 1. The reservoir body 2 is movable between a first and second position within the casing 1.

[0013] The reservoir body 2 has a reservoir cavity 6 in which a liquid drug 7 is stored and which can be topped-up via a re-fill port 23. A plunger 8 is provided within the reservoir body 2 and extends out of the upper (as shown in the figures) end of the reservoir body 2, such that it engages with a cap 9 which covers the top of the device 25. A plunger return spring 10 is provided which extends from the reservoir body 2 and biases the plunger 8 out of the reservoir cavity 6.

[0014] A metering cavity 12 is provided at the lower end of the reservoir cavity 6 and the metering cavity 12 is in liquid communication, via a one-way ball valve 13, with a dispensing conduit or tube 14 provided within the lower end of the reservoir body 2. An elastomeric diaphragm 15 is provided around the lower portion of the

reservoir body 2 and is joined at its outer edge to the casing 1 by diaphragm clamp 11a and a seal 11, which is an O-ring, to define, together with the reservoir body 2 and the casing 1, a chamber V1.

[0015] The spray head mounting assembly 3 is provided with an outlet 26 covered by a membrane 16 which, together with the lower portion of the reservoir body 2, the spray head mounting assembly 3 and the elastomeric diaphragm 15, defines a chamber V2. The membrane 16 is retained by a seal 17 and is provided with a perforate portion 27 over which a holding reservoir 18 is provided and which can receive liquid drug 7 through the dispensing conduit or tube 14 in use. The perforate portion 27 of the membrane 16 has perforations 50 (see Figs. 8a and 8b) of a reverse taper and this is described in greater detail with reference to Figs 8a and 8b.

[0016] The holding reservoir 18 is preferably cylindrical and, at the end adjacent the membrane 16, entirely surrounds the perforate portion 27. In the cylindrical arrangement, it is preferred that the opposing sides of the reservoir 18 are generally perpendicular to the face of the membrane.

[0017] The spray head mounting assembly 3 is provided with a damping inlet valve 19 leading into the chamber V1, a first one-way exhaust valve 20 from the chamber V1 and a second one-way exhaust valve 21 from the chamber V2.

[0018] Fig. 1 shows the device 25 at rest prior to metering a predefined dose of drug 7 into the holding reservoir 18. In this state, both the main return spring 5 and the plunger return spring 10 are extended so that the reservoir body 2 and the plunger 8 have been pushed fully upwards against physical stops (not shown).

[0019] The elastomeric diaphragm 15 is stretched from its normally flat state and acts as a flexible wall, separating the two chambers V1 and V2. These chambers are initially at ambient pressure and the perforations 50 in the perforate portion 27 of membrane 16 are dry and open.

[0020] The operation of the device shown in Fig. 1 will now be described with reference to Figs. 2 to 6.

[0021] To initiate operation of the device 25, the cap 9 is pressed downwards 9a (see Fig. 2). The reservoir body 2 and the plunger 8 are moved downwards at approximately the same rate, compressing the main return spring 5 until the reservoir body 2 reaches physical stops 28. At this stage the force exerted on the plunger return spring 10 is less than its preload. The lower end of the dispensing conduit or tube 14 is now positioned close to the inner surface of the membrane 16.

[0022] The reservoir body 2 forms an air-tight sliding seal with the casing 1. Therefore, as the reservoir body 2 descends, air is displaced from the chamber V1, through the first one-way exhaust valve 20 and the elastomeric diaphragm 15 returns towards its relaxed, almost flat state. At the same time, air is displaced from the chamber V2 through the second one-way exhaust

valve 21, through the damping valve 19, and through the perforate portion 27 of the membrane 16.

[0023] As can be seen in Fig. 3, once the reservoir body 2 has reached its physical stops 28, further depression of the cap 9 compresses the plunger return spring 10. This pushes 8a the plunger 8 into the metering cavity 12 (see Fig. 1). The plunger 8 is provided with a plunger seal 24 which engages with the side wall 12a of the metering cavity 12 to form a seal therewith. This traps a metered dose of the liquid drug 7 in the metering cavity 12. The sealing pressure of the plunger seal 24 against the side-wall 12a of the metering cavity 12 is greater than the sealing pressure of the elastomeric ball valve 13 against the ball valve seat 13a. Therefore, as the plunger 8 is depressed further, the trapped dose of liquid drug 7 is displaced from the metering cavity 12 past 13b the one-way elastomeric ball valve 13, through the dispensing conduit or tube 14 and into the holding reservoir 18. The holding reservoir 18 has a side-wall 22 which is either coated with or formed of PTFE. In this configuration, all of the perforations 50 in the perforate portion 27 of membrane 16 are now covered with liquid drug 7a.

[0024] Once the cap 9 is released, as shown in Fig. 4, the plunger return spring 10 starts to expand, pushing 8b the plunger 8 out of the metering cavity 12, thus creating a partial vacuum in the metering cavity 12. The elastomeric ball valve 13 remains closed. The plunger return spring 10 is strong enough to overcome this partial vacuum so as to push 8b the plunger 8 clear of the metering cavity 12 until it reaches a physical stop (not shown). This partial vacuum pressure reduces as the plunger 8 is withdrawn 8b from the metering cavity 12 until the pressure drop across the plunger seal 24 exceeds the sealing pressure against the side-wall 12a of the metering cavity 12. A small amount of liquid drug 7 can then flow past the plunger seal 24 into the metering cavity 12 as the plunger 8 is withdrawn 8b. The main return spring 5 is able to extend, pushing 2a the reservoir body 2 upwards as shown in Fig. 5. This then causes the chambers V1 and V2 to expand and the elastomeric diaphragm 15 to stretch.

[0025] Air cannot enter through the one-way valves 20, 21 or through the perforate portion 27 of membrane 16 as the perforations 50 are now covered by liquid drug 7a. The perforations 50 resist air ingress because of the surface tension of the liquid drug forming menisci across the perforations 50 in the perforate portion 27 and therefore, as the chambers V1 and V2 expand, the pressures within those chambers decrease below ambient pressure. The reservoir body 2 continues to move upwards 2a until the restoring force of the main return spring 5 is stalled by the opposing forces created, in the main, by the negative pressures in the chambers V1 and V2 and by the tension in the elastomeric diaphragm 15.

[0026] When the damping valve 19 is fully closed, no air can enter the chamber V1 and so the main return spring 5 will not extend far before it is stalled by the neg-

ative pressures generated in the chambers V1, V2 and by tension in the blastomeric diaphragm 15.

[0027] However, when the damping valve 19 is slightly open, it will allow air to enter into, and conversely exhaust from, the chamber V1 at a rate determined by the restoring force of the main return spring 5. Therefore, as the main return spring 5 pushes the reservoir body 2 upwards 2a, the volume of chamber V1 expands at a controlled rate until the reservoir body 2 reaches a pre-defined physical stop (not shown) (see Fig. 6).

[0028] The main return spring 5 also causes the blastomeric diaphragm 15 to stretch at a controlled rate which, in turn, causes the volume of the chamber V2 to expand at a controlled rate. The pressure within the chamber V2 behind the spray head assembly 3a therefore reduces at a controlled rate.

[0029] The physical stop (not shown) for the upward movement of the reservoir body 2 limits the extension of the stretched blastomeric diaphragm 15 and defines the final volume change of the chamber V2 and thus the target negative pressure achieved in V2. At this stage, the pressure in the chamber V1 is at ambient pressure.

[0030] Therefore, the net result is that the target (operating) negative pressure, which is close to the bubble point pressure for the spray head assembly 3a (the bubble point pressure being the pressure differential at which air bubbles enter the chamber V2 through the perforations 50 in the perforate portion 27, by overcoming the surface tension of the menisci of liquid drug), can be reached at a controlled rate without air being ingested through the membrane 16.

[0031] If the negative pressure in the chamber V2 is generated too quickly, i.e. by opening the damping valve 19 too far, then the surface tension of the liquid drug covering the perforations in the perforate portion 27 of the membrane 16 will be overcome. Air will then be ingested rapidly through the perforate portion 27, hence cancelling the negative pressure in the chamber V2. In the absence of a negative pressure, the drug dispensing device 25 will not generate a spray.

[0032] It should be noted that the rate of air admission and exhaustion through damping valve 19 is much less than the rate of exhaustion through the first one way exhaust valve 20.

[0033] An electronic control circuit 30 as shown in Fig. 7 triggers the delivery of the liquid drug through the perforate portion 27 of the membrane 16 by controlling membrane actuating means (not shown) such as piezo-electrically activated vibrating means. The control system uses a small hot wire anemometer 39 to monitor air flow into the drug delivery system. The anemometer 39 senses when a patient is inhaling and trying to trigger the spray head delivery.

[0034] The maximum spring load of the plunger return spring 10 preferably should not exceed 20N. This therefore limits the force that a user must exert in order to operate the device.

[0035] The plunger return spring 10 is preloaded and

this preload should be greater than the fully compressed load in the main return spring 5. This ensures that the reservoir body 2 is fully down against its physical stop 28 before the dose is metered into the holding reservoir 18. If the dose is metered from the dispensing aperture 14 when the reservoir body 2 is not fully down, all or part of the dose may miss the holding reservoir 18. The target negative pressure in the chamber V2 will then not be reached when the cap 9 is released because the perforations in the perforate portion 27 of the membrane 16 will remain dry and open.

[0036] As the plunger 8 is withdrawn 8b from the reservoir cavity 12 a partial vacuum is created between the closed one-way blastomeric ball-valve 13 and the plunger seal 24. The spring force range of the plunger return spring 10 must be sufficient to lift the plunger 8 out of the reservoir cavity 12 when the cap 9 when the cap is released, in order to create a pressure difference across the plunger seal 24 (between the liquid drug 7 in reservoir cavity 6 and the blastomeric ball valve 13) which exceeds the sealing pressure of the plunger seal 24 against the side-wall 12a of the reservoir cavity 12. Liquid drug 7 is then able to flow past the plunger seal 24 and into the reservoir cavity 12 as the plunger 8 is withdrawn 8b. This has the advantage of minimising foam generation within the reservoir cavity 12 especially with liquid drugs containing surfactants as part of their formulation.

[0037] The spring force range of the main return spring 5 must be sufficient to lift the reservoir body 2 against the negative pressures generated within the chambers V1, V2, the stretching of the blastomeric diaphragm 15 and the friction of the sliding seal between the reservoir body 2 and the casing 1.

[0038] The maximum tension in the blastomeric diaphragm 15, which is achieved when the reservoir body 2 is at rest, must be high enough to maintain the target negative pressure within the chamber V2 without the blastomeric diaphragm 15 deforming under that negative pressure. This tensional force must not be high enough to prevent the main return spring 5 from lifting the reservoir body 2 up against the predetermined physical stop during the generation of the negative pressures.

[0039] In summary, the extension force of the plunger return spring 10 is greater than the extension force of the main return spring 5 which is greater than the tensional force of the blastomeric diaphragm 15.

[0040] From Fig. 7, it can be seen that the control circuit employs two operational amplifiers (op-amps) 31, 32, which can supply output voltages over the full power supply range, i.e. between the supply voltage Vcc and ground GND. Op-amp 31 is in closed loop configuration with a Wheatstone bridge to maintain a constant resistance of the anemometer filament 39. The drive voltage 40 for the Wheatstone bridge is supplied to the op-amp 32 which is configured as a voltage comparator. The comparator is a switching device having a measurement

input and a reference input. When the measurement voltage 33 is higher than the reference voltage 34, the output 35 from the op-amp 32 switches from GND to Vcc.

[0041] Circuits of this type are well known in anemometry. However the circuit of Fig. 7 shows a simple implementation of a circuit which can discriminate between high and low rates of change of air flow. The RC time constant used for the reference voltage 34 is set so that it can respond, in a damped manner, to slowly varying conditions such as changes in ambient conditions and to the normal slow breathing of a patient. Therefore, the reference voltage 34 is insensitive to fast rates of change in air flow during the patient inhalation cycle. The measurement voltage 33 at the comparator op-amp 32 is an attenuated signal from the Wheatstone bridge drive voltage 40, but does not have a long time constant filter and so reacts directly with the patient's inhalation.

[0042] If the patient inhales at a sufficiently high volume rate, then the measurement voltage 33 will exceed the reference voltage 34 due to the difference in the time constant of the reference and measurement voltages. In order for this to happen, a certain threshold of rate of change of air flow must be exceeded. When the measurement voltage 33 exceeds the reference voltage input 34, there will be a change in the voltage state at the output 35. Since the comparator circuit does not have any feedback, it is operating in a high gain mode and so has only two output states, 0v and Vcc. Thus, it is possible to couple this circuit directly to TTL logic devices.

[0043] Two variable resistors 36, 37 are provided within the control circuit 30. The variable resistor 36 in the comparator is used to adjust the level of attenuation applied to the measurement voltage 33, which sets the sensitivity of the circuit to the rate of change of patient's inhalation. The second variable resistor 37, in the Wheatstone bridge, is provided to set the temperature of the anemometer filament 39 and is used to set the minimum rate of change of air flow that the circuit can detect. Thus, these adjustments allow a high degree of flexibility in the installation of the anemometer as a breath trigger device.

[0044] A field effect transistor 38 is used to alter the reference ratio of the Wheatstone bridge thus enabling or disabling the air flow sensor via "ENABLE". In this way, the power consumption of the control circuit 30 is reduced, allowing the device to have a useful operating life when powered by batteries.

[0045] Figure 8a shows cross-sectional detail of a first example perforate membrane 16, which is operable to vibrate substantially in the direction of arrow 58 and which is suitable for use with the drug dispensing device 25 to produce fine aerosol sprays. In one embodiment, the membrane 16 comprises a circular layer of polymer which contains a plurality of tapered conical perforations 50. Each perforation 50 has openings 53 in the front exit face and openings 54 in the rear entry face, which perforations are laid out in a square lattice. Such perfora-

tions may be introduced into polymer membranes by, for example, laser-drilling with an excimer laser.

[0046] Figure 8b shows cross-sectional detail of a second example perforate membrane 2016, which membrane is operable to vibrate substantially and suitable for use with drug dispensing device 25 in the direction of arrow 58. The membrane is formed as a circular disc of diameter 8mm from electroformed nickel, and is manufactured, for example, by Stork Veco of Eerbeek, The Netherlands. Its thickness is 70 microns and is formed with a plurality of perforations shown at 2050 which, at 'front' face 2051, are of diameter shown at "a" of 120 microns and at 'rear' face 2052 are of diameter shown at "b" of 30 microns. The perforations are laid out in an equilateral triangular lattice of pitch 170µm. The profile of the perforations varies smoothly between the front and rear face diameters through the membrane thickness with substantially flat 'land' regions (shown at "c") of smallest dimension 50µm in front face 2051.

#### Claims

1. An aerosol drug dispensing device in which a metered dose of a pharmacologically active liquid is provided to a holding reservoir from which the dose is then dispensed as an aerosol spay through a perforate membrane including perforations having a reverse taper, namely a larger cross-sectional area at that face of the membrane away from which liquid droplets emerge than at the opposite face of the membrane, **characterised in that:**

the holding reservoir has a containment wall or walls having a surface coated with or formed of a fluoropolymer.

2. A device according to claim 1, wherein the holding reservoir is coated with or formed from polytetrafluoroethylene.
3. A device according to either claim 1 or claim 2, wherein the reservoir is provided with an inlet for receiving the pharmacologically active liquid from a supply means.
4. A device according to claim 3, wherein the perforate portion is formed from a metal.




Figure 1




Figure 2




Figure 3






Figure 4




Figure 5




Figure 6




Figure 7

Figure 8a





Figure 8b





European Patent  
Office

# EUROPEAN SEARCH REPORT

Application Number

EP 01 30 9421

DOCUMENTS CONSIDERED TO BE RELEVANT			
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (Int.Cl.7)
D, Y	WO 95 15822 A (HUMBERSTONE VICTOR CAREY ; SANT ANDREW JONATHAN (GB); TECHNOLOGY PA) 15 June 1995 (1995-06-15) * the whole document *	1-4	A61M15/00
Y	WO 99 42154 A (BESPAK PLC ; WARBY RICHARD JOHN (GB)) 26 August 1999 (1999-08-26) * abstract * * page 6, line 25 - page 9, line 11; claims 1-3 *	1-4	
A	WO 00 64779 A (BONNEY STANLEY GEORGE ; DAVIES MICHAEL BIRSHA (GB); GODFREY JAMES W) 2 November 2000 (2000-11-02) * page 15, line 18-22 *	1	
A	WO 00 55072 A (ANDERSON GREGOR JOHN MCLENNAN ; JONES ANTHONY PATRICK (GB); RAND PA) 21 September 2000 (2000-09-21) * abstract * * page 23, line 16-23 *	1	
A	US 5 758 637 A (IVRI YEHUDA ET AL) 2 June 1998 (1998-06-02) * abstract *	1	TECHNICAL FIELDS SEARCHED (Int.Cl.7)  A61M B05B
A	EP 0 542 723 A (BESPAK PLC) 19 May 1993 (1993-05-19) * abstract *	1	
The present search report has been drawn up for all claims			
Place of search <b>BERLIN</b>		Date of completion of the search <b>25 February 2002</b>	Examiner <b>Nielsen, M</b>
CATEGORY OF CITED DOCUMENTS X : particularly relevant if taken alone Y : particularly relevant if combined with another document of the same category A : technological background O : non-written disclosure P : intermediate document		T : theory or principle underlying the invention E : earlier patent document, but published on or after the filing date D : document cited in the application L : document cited for other reasons & : member of the same patent family, corresponding document	

EPO FORM 1503 (01-99) (PUC01)

# ANNEX TO THE EUROPEAN SEARCH REPORT ON EUROPEAN PATENT APPLICATION NO.

EP 01 30 9421

This annex lists the patent family members relating to the patent documents cited in the above-mentioned European search report. The members are as contained in the European Patent Office EDP file on. The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

25-02-2002

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 9515822	A	15-06-1995	AT 171654 T	15-10-1998
			AU 687136 B2	19-02-1998
			AU 1195995 A	27-06-1995
			BR 9408281 A	17-12-1996
			CA 2176573 A1	15-06-1995
			CZ 9601681 A3	17-09-1997
			DE 69413708 D1	05-11-1998
			DE 69413708 T2	25-02-1999
			DK 732975 T3	21-06-1999
			EP 0732975 A1	25-09-1996
			ES 2123227 T3	01-01-1999
			WO 9515822 A1	15-06-1995
			JP 10502570 T	10-03-1998
			US 5823428 A	20-10-1998
WO 9942154	A	26-08-1999	AU 742080 B2	20-12-2001
			AU 2540199 A	06-09-1999
			BR 9908151 A	31-10-2000
			CN 1291109 T	11-04-2001
			EE 200000484 A	15-08-2001
			EP 1088567 A2	04-04-2001
			EP 1066073 A1	10-01-2001
			WO 9942154 A1	26-08-1999
			HR 20000548 A1	31-08-2001
			HU 0101459 A2	28-09-2001
			JP 2001190669 A	17-07-2001
			NO 20004196 A	22-08-2000
			PL 342515 A1	18-06-2001
			SK 12702000 A3	12-03-2001
			TR 200002439 T2	21-12-2000
WO 0064779	A	02-11-2000	AU 4119500 A	10-11-2000
			WO 0064779 A1	02-11-2000
			EP 1173368 A1	23-01-2002
WO 0055072	A	21-09-2000	AU 3158700 A	04-10-2000
			BR 0008867 A	02-01-2002
			WO 0055072 A2	21-09-2000
			EP 1169244 A2	09-01-2002
			TW 446565 B	21-07-2001
US 5758637	A	02-06-1998	US 5586550 A	24-12-1996
			AU 711059 B2	07-10-1999
			AU 7010096 A	19-03-1997
			BR 9606617 A	30-09-1997
			CA 2203926 A1	06-03-1997

EPC FORM 2006

For more details about this annex : see Official Journal of the European Patent Office, No. 12/82

**ANNEX TO THE EUROPEAN SEARCH REPORT  
ON EUROPEAN PATENT APPLICATION NO.**

EP 01 30 9421

This annex lists the patent family members relating to the patent documents cited in the above-mentioned European search report. The members are as contained in the European Patent Office EDP file on  
The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

25-02-2002

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
US 5758637 A		EP 0794838 A1	17-09-1997
		JP 10508251 T	18-08-1998
		US 6085740 A	11-07-2000
		WO 9707896 A1	06-03-1997
EP 0542723 A	19-05-1993	AT 93418 T	15-09-1993
		EP 0542723 A2	19-05-1993
		EP 0718046 A2	26-06-1996
		AT 143295 T	15-10-1996
		AT 194511 T	15-07-2000
		AU 637658 B2	03-06-1993
		AU 6789790 A	23-07-1992
		BR 9006291 A	24-09-1991
		CA 2031907 A1	13-06-1991
		CN 1054916 A ,B	02-10-1991
		DE 69002926 D1	30-09-1993
		DE 69028718 D1	31-10-1996
		DE 69033591 D1	17-08-2000
		DE 69033591 T2	23-11-2000
		DK 432992 T3	10-01-1994
		DK 542723 T3	03-03-1997
		EP 0432992 A1	19-06-1991
		ES 2030348 A6	16-10-1992
		ES 2043293 T3	16-12-1993
		ES 2092146 T3	16-11-1996
		FI 906089 A	13-06-1991
		FI 931780 A	20-04-1993
		FR 2655572 A1	14-06-1991
		GB 2240494 A ,B	07-08-1991
		GB 2263076 A ,B	14-07-1993
		IE 904468 A1	19-06-1991
		IL 96597 A	12-04-1994
		IT 1244181 B	08-07-1994
		JP 1917114 C	23-03-1995
		JP 4100557 A	02-04-1992
		JP 6040984 B	01-06-1994
		KR 152086 B1	01-10-1998
		MX 172730 B	10-01-1994
		NO 179275 B	03-06-1996
		NZ 236418 A	23-12-1992
		PT 96169 A ,B	31-08-1992
		RU 2051755 C1	10-01-1996
		US 5152456 A	06-10-1992
		US 5261601 A	16-11-1993
		ZA 9009776 A	26-08-1992

EPO FORM P246

For more details about this annex : see Official Journal of the European Patent Office, No 12/82